
    
      This study is being conducted to determine the potential of lapaquistat acetate 50 mg per day
      to lower LDL-C levels compared with placebo. This study is also being conducted to further
      evaluate the safety and tolerability of lapaquistat acetate 50 mg over a period of 12 weeks.
      An optional, 48-week, open-label extension will follow the 12 week, double-blind treatment
      period to evaluate the long-term safety and tolerability of lapaquistat acetate 50 mg/day.
    
  